Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
November 05 2020 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical
company focused on discovering and developing novel products to
treat cancer, today announced that the Company intends to release
its third quarter financial results on Thursday, November 12, 2020
after market close. Management plans to host a conference call and
live webcast at 4:30 p.m. Eastern time on that day to discuss these
results and provide an update on its pipeline programs.
Conference Call and Webcast
InformationInterested parties who wish to participate in
the conference call may do so by dialing (855) 428-5741 (U.S.) and
(210) 229-8823 (International) and using conference ID 8687160.
To facilitate an on-time conference call start,
Onconova recommends that participants dial in 15 minutes before the
4:30 p.m. ET start time.
Those interested in listening to the conference
call via the internet may do so by visiting the investors and media
page on the company's website at www.onconova.com and clicking on
the webcast link. In addition to the live webcast, a replay will be
available on the Onconova website for 90 days following the
call.
About Onconova Therapeutics,
Inc.Onconova Therapeutics is a biopharmaceutical company
focused on discovering and developing novel products to treat
cancer. The Company has proprietary targeted anti-cancer agents
designed to disrupt specific cellular pathways that are important
for cancer cell proliferation.
Onconova’s novel, proprietary, CDK4/6 + ARK5
inhibitor, ON 123300 is currently in a dose escalation and
expansion Phase 1 trial in China, and the IND filing in the U.S. is
anticipated in the fourth quarter of 2020. Onconova’s RAS pathway
inhibitor, oral rigosertib, is currently in a dose escalation and
expansion Phase 1 investigator-initiated study (IIS) targeting
patients with KRAS+ lung adenocarcinoma in combination with
nivolumab. Preclinical work with rigosertib in COVID-19 is ongoing
as well.
For more information, please visit
https://www.onconova.com.
Forward-Looking StatementsSome
of the statements in this release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
and involve risks and uncertainties. These statements relate to
Onconova expectations regarding its clinical development plans and
patents. Onconova has attempted to identify forward-looking
statements by terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. Although Onconova
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including the success and timing
of Onconova's clinical trials and regulatory approval of protocols,
Onconova’s ability to continue as a going concern, the need for
additional financing, our collaborations, and those discussed under
the heading "Risk Factors" in Onconova's most recent Annual Report
on Form 10-K and quarterly reports on Form 10-Q. Any
forward-looking statements contained in this release speak only as
of its date. Onconova undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Press release contact
information
Company Contact:Avi
OlerOnconova Therapeutics, Inc.267-759-3680 ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:LHA Investor
Relations Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024